OSSIO is a medical technology company developing OSSIOfiber®, a bio-integrative orthopedic fixation implant that promotes natural bone healing and eliminates the need for permanent metal hardware.[1][3][5] It targets the $15B+ orthopedic fixation market (screws, pins, plates), serving orthopedic and podiatric surgeons treating patients with fractures or deformities like hammertoe, by solving issues such as implant-related complications, pain, hardware removal surgeries, and poor healthcare economics.[1][2][3] Adopted by over 2,200 surgeons across the US, OSSIOfiber uses existing surgical techniques and reimbursement codes, with full bone integration in 18-24 months and 100% patient satisfaction in recent hammertoe studies.[1][3]
Founded in 2014 in Cesarea, Israel, OSSIO emerged from years of biomechanical research aiming to create "bio-integrative" implants that combine mechanical strength with natural bone regrowth, addressing gaps in traditional metal and resorbable options.[1][2] Orahn Preiss-Bloom, the Founder and Chief Innovation Officer, drove the technological foundation of OSSIOfiber.[1] Under CEO Brian Verrier, the company expanded commercially, recently establishing U.S. headquarters in Palmetto, Florida (near Tampa), converting 30,000 sq ft into manufacturing and training facilities, and planning ~100 new jobs over five years to fuel growth.[2]
OSSIO rides the trend toward bio-integrative orthopedics, replacing permanent metal in a multibillion-dollar market amid rising demand for patient-centric, complication-free surgeries and value-based healthcare.[1][2][5] Timing aligns with advances in material science enabling strong, non-inflammatory implants, countering metal's 10-20% removal rates and resorbables' inconsistencies.[5] Market forces like aging populations, orthopedic procedure growth, and payor pressure for cost savings favor OSSIOfiber's economics and outcomes, positioning OSSIO to disrupt a stagnant field unchanged in over 100 years.[2][3] It influences the ecosystem by validating "bio-integratives" as a new category, encouraging surgeon training and adoption while boosting life sciences hubs like Florida.[2]
OSSIO is poised to expand OSSIOfiber across major orthopedic segments (e.g., trauma, sports medicine) via its Florida manufacturing scale-up and job growth, targeting broader U.S./global adoption.[2] Trends like personalized implants, AI-optimized biomaterials, and regulatory tailwinds for non-metal alternatives will accelerate penetration, potentially capturing significant share in the $15B+ market.[1][2] Its influence may evolve from niche innovator to industry standard, transforming bone healing by prioritizing natural regeneration over hardware—ultimately making metal implants obsolete, as envisioned from its 2014 origins.[1][5]
Ossio has raised $50.0M in total across 2 funding rounds.
Ossio's investors include Questa Capital, Vitalize Venture Group.
Ossio has raised $50.0M across 2 funding rounds. Most recently, it raised $28.0M Series D in December 2024.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Dec 1, 2024 | $28.0M Series D | Questa Capital, Vitalize Venture Group | |
| Mar 1, 2019 | $22.0M Series A |
